Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160257 | 0.91 | LMNA (0.44) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL4150527 | 0.80 | ALDH1A1 (0.59) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL4173745 | 0.80 | MLYCD (0.48) | TP53ALDH1A1CYP3A4KMT2AMEN1 | |
| SCHEMBL21227227 | 0.78 | KMT2A (0.48) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL4158666 | 0.78 | TP53 (0.60) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL4157179 | 0.77 | TP53 (0.63) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL4158995 | 0.75 | MLYCD (0.50) | ALDH1A1MLYCD | |
| SCHEMBL4152992 | 0.74 | ALDH1A1 (0.50) | TP53ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL30957369 | 0.72 | TP53 (0.61) | TP53ALDH1A1CYP3A4LMNATRPM8 | |
| SCHEMBL30957368 | 0.72 | TP53 (0.61) | TP53ALDH1A1CYP3A4LMNATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | TP53 1939/4885ALDH1A1 2505/4885CYP3A4 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.